Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
16 Avril 2024 - 12:24PM
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First
Quarter of 2024
Company Announcement
- Net sales of
DARZALEX® in the first quarter of 2024 totaled USD 2,692
million
- Genmab
receives royalties on worldwide net sales from Janssen Biotech,
Inc. (Janssen)
COPENHAGEN, Denmark; April 16, 2024 –
Genmab A/S (Nasdaq: GMAB) announced today
that worldwide net trade sales of
DARZALEX® (daratumumab),
including sales of the subcutaneous (SC) product (daratumumab and
hyaluronidase-fihj, sold under the tradename DARZALEX
FASPRO® in the U.S.),
as reported by Johnson & Johnson were USD 2,692 million
in the first quarter of 2024. Net trade sales were USD
1,464 million in the U.S. and USD 1,228 million in the rest of the
world. Genmab receives royalties on the worldwide net sales of
DARZALEX, both the intravenous and SC products, under the exclusive
worldwide license to Janssen to develop, manufacture and
commercialize daratumumab.
About Genmab Genmab is an international
biotechnology company with a core purpose guiding its unstoppable
team to strive towards improving the lives of patients through
innovative and differentiated antibody therapeutics. For 25 years,
its passionate, innovative and collaborative team has invented
next-generation antibody technology platforms and leveraged
translational, quantitative, and data sciences, resulting in a
proprietary pipeline including bispecific T-cell engagers,
next-generation immune checkpoint modulators, effector function
enhanced antibodies, and antibody-drug conjugates. To help develop
and deliver novel antibody therapies to patients, Genmab has formed
20+ strategic partnerships with biotechnology and pharmaceutical
companies. By 2030, Genmab’s vision is to transform the lives of
people with cancer and other serious diseases with
knock-your-socks-off (KYSO®) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark with locations in Utrecht, the Netherlands, Princeton, New
Jersey, U.S., and Tokyo, Japan. For more information, please
visit Genmab.com and follow us on LinkedIn and
X.
Contact:
Marisol Peron, Senior Vice President, Global Communications &
Corporate AffairsT: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor RelationsT: +45
3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements.
The words “believe,” “expect,” “anticipate,” “intend” and “plan”
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with preclinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab’s most recent financial reports, which are
available on www.genmab.com and the risk factors included in
Genmab’s most recent Annual Report on Form 20-F and other filings
with the U.S. Securities and Exchange Commission (SEC), which are
available at www.sec.gov. Genmab does not undertake any obligation
to update or revise forward looking statements in this Company
Announcement nor to confirm such statements to reflect subsequent
events or circumstances after the date made or in relation to
actual results, unless required by law. Genmab A/S and/or its
subsidiaries own the following trademarks: Genmab®; the Y-shaped
Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®;
HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
DARZALEX® and DARZALEX FASPRO® are trademarks of Johnson &
Johnson.
Company Announcement no. 29 CVR no. 2102 3884 LEI Code
529900MTJPDPE4MHJ122
Genmab A/SCarl Jacobsens Vej 302500 Valby Denmark
- 20240416_CA29_DARZALEX Q1 sales
Genmab AS (TG:GE9)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Genmab AS (TG:GE9)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024